Russia has made progress in developing a vaccine against the Marburg virus, according to Russian Health Minister Mikhail Murashko. The Vektor Center, a Russian research institute specializing in virology and biotechnology, has successfully completed preclinical trials and is preparing documents for clinical trials.
Russia has made significant progress in developing a vaccine against the Marburg virus, Russian Health Minister Mikhail Murashko said at the recent meeting of BRICS health ministers. He said promising research is also underway to combat Lassa fever and West Nile fever.
“We have already developed an effective vaccine against the Ebola virus, and our scientists are currently working on vaccines against the Marburg virus, Lassa fever and West Nile fever,” Mikhail Mourashko said. He also invited BRICS member countries to collaborate in this area, emphasizing Russia’s willingness to share its know-how and scientific capabilities.
The Vektor Research Center, a Russian research institute specializing in virology and biotechnology, is involved in the development of vaccines against viruses, in particular against the Marburg virus. According to information from Rospotrebnadzor, the Russian agency responsible for public health and consumer protection, the preclinical testing phase has already been successfully completed, and the preparation of the necessary documents to launch clinical trials is underway.
What is Marburg virus?
The Marburg virus, which belongs to the same family as the Ebola virus, is the cause of serious epidemics, particularly in Africa. First identified in 1967, it causes an illness characterized by high fever, internal bleeding and serious neurological damage. The mortality rate can vary from 24 to 88% depending on the strain of the virus and health conditions.
The virus is primarily transmitted by fruit bats, including the Egyptian fruit bat, but it also spreads from human to human through contact with the bodily fluids of an infected person.
